Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Study of the RelayPro Thoracic Stent-Graft in Subjects With an Acute, Complicated Type B Aortic Dissection
NCT03033043 · View on ClinicalTrials.gov ↗
Study Summary
This clinical trial is a prospective, multicenter, non-blinded, non-randomized study designed to assess the RelayPro thoracic endografts in the treatment of acute, complicated type B aortic dissection. The primary endpoint will measure all-cause mortality at 30 days post-procedure.
Conditions Studied
Interventions
- DEVICE Relay Pro Stent-Graft
Study Locations (20)
Connecticut
- Hartford Hospital — Hartford
- Yale School of Medicine — New Haven
Ohio
- University Hospitals — Cleveland
- Cleveland Clinic Foundation — Cleveland
Pennsylvania
- University of Pennsylvania Medical Center / Penn Presbyterian — Philadelphia
- Lankenau Medical Center — Wynnewood
Virginia
- Sentara Heart Hospital — Norfolk
- Carilion Roanoke Memorial Hospital — Roanoke
California
- USC Department of Surgery — Los Angeles
Colorado
- University of Colorado Denver — Aurora
District of Columbia
- Medstar Washington Hospital Center — Washington D.C.
Georgia
- Emory University — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2017-12-14 |
| Est. Completion | 2026-11 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03033043
The ClinicalTrials.gov registry entry for NCT03033043 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bolton Medical, which has 36 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Aortic Dissection Type B appearing as the primary indexed condition, and to 1 intervention — of which Relay Pro Stent-Graft is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03033043 reports 20 study locations spanning 16 distinct geographic areas — top geographies include Connecticut, Ohio, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03033043 about?
NCT03033043 is a clinical study titled "Study of the RelayPro Thoracic Stent-Graft in Subjects With an Acute, Complicated Type B Aortic Dissection". This clinical trial is a prospective, multicenter, non-blinded, non-randomized study designed to assess the RelayPro thoracic endografts in the treatment of acute, complicated type B aortic dissection. The primary endpoint will measure all-cause mortality at 30 days post-procedure.
What is the current status of trial NCT03033043?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 56 participants. The study started on 2017-12-14. Estimated completion is 2026-11.
What conditions does trial NCT03033043 study?
This clinical trial studies the following conditions: Aortic Dissection Type B. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03033043?
The interventions under investigation include: Relay Pro Stent-Graft (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03033043?
This trial is sponsored by Bolton Medical, which has 36 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03033043 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.